Medscape

First-in-Human Trial Supports Safety, Feasibility of Stem Cell Therapy in Prenatal Spina Bifida Repair

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal ...
Seeking Alpha

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Pluri (PLUR), an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) ...
Fierce Biotech

As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

Cellipont Bioservices and Soter Bio Announce Strategic Collaboration to Support Integrated U.S. Cell Therapy Manufacturing

"Soter Bio was built to support advanced therapeutic programs that depend on reliable, rapid, scalable input materials," said Mike Stewart, Founder and CEO of Soter Bio. "Partnering with Cellipont ...

More sensitive HIT cell therapy shows promise against solid cancers

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, ...
BioSpace

Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In

The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
Rutland Herald

PHCbi Launches LiCellGrow™ Cell Expansion System to Support High-Quality and Efficient Production of Cell and Gene Therapies

PHCbi will exhibit LiCellGrow™ at the 25th Congress of the Japanese Society for Regenerative Medicine, March 19-20 at the Kobe International Conference Center and Kobe International Exhibition Center ...

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Feb 23 (Reuters) - Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of ...
Seeking Alpha

AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need

TOKYO--(BUSINESS WIRE)-- AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical ...
MarketWatch

CaseBioscience(R) Launches CaseCryo(R) CTG DMSO and CaseStor(R) HSS at ATW 2026, Advancing Next-Generation Biopreservation for Cell Therapy

The MarketWatch News Department was not involved in the creation of this content. Introducing cell therapy--grade cryopreservation and hypothermic storage solutions designed for consistency, quality, ...
BioSpace

Cashing In on ‘Creative Fundamentals’ To Fund Rare Disease R&D

Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations.
Fierce Biotech

Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking

Galapagos took a 228 million euro ($269 million) hit last year as it began to close its cell therapy business, but the Belgian biopharma is confident it can stabilize its finances by the end of the ...